Equillium (NASDAQ:EQ) COO Christine Zedelmayer Sells 100,000 Shares

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 100,000 shares of the business’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $1.50, for a total transaction of $150,000.00. Following the completion of the sale, the chief operating officer owned 91,444 shares of the company’s stock, valued at $137,166. The trade was a 52.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Christine Zedelmayer also recently made the following trade(s):

• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The shares were sold at an average price of $1.31, for a total transaction of $15,589.00.
• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The stock was sold at an average price of $1.34, for a total transaction of $31,897.36.
• On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The stock was sold at an average price of $0.95, for a total transaction of $7,693.10.

Equillium Price Performance

EQ stock opened at $1.35 on Wednesday. The stock has a market capitalization of $82.20 million, a price-to-earnings ratio of -2.18 and a beta of 1.92. The company has a 50-day moving average of $1.15 and a two-hundred day moving average of $1.03. Equillium, Inc. has a 52-week low of $0.27 and a 52-week high of $2.35.

Equillium (NASDAQ:EQ) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.08. Equities analysts expect that Equillium, Inc. will post 0.14 EPS for the current fiscal year.

Analysts Set New Price Targets

EQ has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research note on Monday. Wall Street Zen raised shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and an average target price of $1.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC acquired a new position in shares of Equillium in the 3rd quarter valued at $7,951,000. Woodline Partners LP acquired a new stake in shares of Equillium during the 3rd quarter valued at about $5,018,000. Vanguard Group Inc. increased its stake in Equillium by 59.4% in the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock valued at $1,879,000 after acquiring an additional 489,855 shares during the period. Cantor Fitzgerald L. P. acquired a new position in Equillium in the third quarter worth about $608,000. Finally, Aberdeen Group plc bought a new position in Equillium during the third quarter worth about $543,000. 27.05% of the stock is owned by institutional investors.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.